StockNews.com assumed coverage on shares of Calithera Biosciences (NASDAQ:CALA – Get Rating) in a report released on Friday. The firm issued a hold rating on the biotechnology company's stock.
Calithera Biosciences Stock Performance
NASDAQ:CALA opened at $0.03 on Friday. Calithera Biosciences has a one year low of $0.01 and a one year high of $5.29. The business's 50-day simple moving average is $0.05 and its 200 day simple moving average is $1.12. The stock has a market cap of $121,750.00, a price-to-earnings ratio of 0.00 and a beta of 1.19.
Get Calithera Biosciences alerts:Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of CALA. Alyeska Investment Group L.P. acquired a new position in shares of Calithera Biosciences in the first quarter worth about $404,000. Affinity Asset Advisors LLC bought a new stake in Calithera Biosciences in the first quarter valued at about $404,000. Renaissance Technologies LLC increased its holdings in Calithera Biosciences by 36.5% in the first quarter. Renaissance Technologies LLC now owns 1,853,500 shares of the biotechnology company's stock valued at $749,000 after buying an additional 496,100 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Calithera Biosciences by 143.2% in the first quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company's stock valued at $50,000 after buying an additional 72,865 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in Calithera Biosciences by 23.4% in the third quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company's stock valued at $415,000 after buying an additional 26,800 shares during the last quarter. Institutional investors and hedge funds own 33.73% of the company's stock.
Calithera Biosciences Company Profile
(Get Rating)
Calithera Biosciences, Inc is a clinical stage precision oncology biopharmaceutical company, which engages in developing targeted therapies to redefine treatment for biomarker-specific patient populations. It also focuses on researching small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic.
Featured Articles
- Get a free copy of the StockNews.com research report on Calithera Biosciences (CALA)
- Insiders Drive Volatility For Keurig Dr Pepper
- After a 40% Drop, Analysts Remain Bullish on Impinj
- Visa Charges Higher After Better-Than-Expected Q2 Report
- onsemi Puts A Bottom in Chip Stocks, Heads For New Highs
- Can Teladoc Stock Be Resuscitated?
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
